ARS Pharmaceuticals (SPRY) Short-term Investments (2022 - 2026)

ARS Pharmaceuticals (SPRY) has 5 years of Short-term Investments data on file, last reported at $176.6 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 25.11% year-over-year to $176.6 million; the trailing twelve-month figure through Mar 2026 stood at $176.6 million (down 25.11% YoY), and the FY2025 full-year result was $203.7 million, down 22.62% from the prior year.
• Short-term Investments eased to $176.6 million in Q1 2026, from $203.7 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $263.2 million in Q4 2024 to a low of $19.9 million in Q1 2022.
• A 5-year average of $155.7 million and a median of $176.6 million in 2026 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments surged 789.75% in 2023 and decreased 25.11% in 2026, its largest moves.
• Tracing SPRY's Short-term Investments over 5 years: stood at $63.9 million in 2022, then surged by 146.45% to $157.4 million in 2023, then soared by 67.23% to $263.2 million in 2024, then dropped by 22.62% to $203.7 million in 2025, then retreated by 13.27% to $176.6 million in 2026.
• Business Quant data shows SPRY's Short-term Investments at $176.6 million in Q1 2026, $203.7 million in Q4 2025, and $228.7 million in Q3 2025.